SGX-523 is primarily investigated for its potential in cancer therapy, specifically targeting c-Met kinase, a receptor tyrosine kinase involved in various cellular processes including proliferation, survival, and migration. Its application is focused on inhibiting the aberrant signaling pathways associated with c-Met, which are often implicated in the progression and metastasis of certain cancers. By blocking these pathways, SGX-523 aims to halt tumor growth and spread, making it a candidate for treating cancers where c-Met overexpression or mutation is a driving factor. Research and clinical studies are ongoing to evaluate its efficacy and safety in therapeutic use.